BORTEZOMIB DR REDDY'S 3.5mg powder for injection medication leaflet

L01XG01 bortezomib • Antineoplastic and immunomodulating agents | Other antineoplastic agents | Proteasome inhibitors

Bortezomibum is a medication used for the treatment of multiple myeloma and mantle cell lymphoma. It is a proteasome inhibitor that interferes with essential cellular processes in cancer cells, leading to their death.

The medication is administered via subcutaneous or intravenous injection, usually in treatment cycles, as directed by a doctor. The dosage and duration of treatment are adjusted based on the patient's condition and response to therapy.

Common side effects include fatigue, nausea, diarrhea, peripheral neuropathy, and decreased blood cell counts. In rare cases, more severe adverse effects such as heart failure or pulmonary toxicity may occur.

Bortezomibum is not recommended for pregnant or breastfeeding women, as it may affect fetal development. Patients should inform their doctor about all medications they are taking to avoid drug interactions.

General data about BORTEZOMIB DR REDDY'S 3.5mg

Substance: bortezomib

Date of last drug list: 01-06-2025

Commercial code: W62997001

Concentration: 3.5mg

Pharmaceutical form: powder for injection

Quantity: 1

Product type: generic

Price: 4460.12 RON

Prescription restrictions: P-RF - Medicines prescription that is retained in the pharmacy (not renewable).

Marketing authorisation

Manufacturer: BETAPHARM ARZNEIMITTEL GMBH - GERMANIA

Holder: DR. REDDY'S LABORATORIES ROMANIA S.R.L. - ROMANIA

Number: 14171/2021/01

Shelf life: 2 years

Pharmaceutical forms available for bortezomib

Concentrations available for bortezomib

1mg, 2.5mg, 2.5mg/ml, 25mg/ml, 3.5mg

Compensation lists for BORTEZOMIB DR REDDY'S 3.5mg DR. REDDY'S

NHP 3 (C2) - NHP oncology

Price

Copayment

Patient

4460.12 RON

1054.86 RON

3405.26 RON